Advancing the pace of innovative research is a priority for ALSF. We take risks to fund proposals embracing innovation that have been deemed highly important but have not received National Institutes of Health funding, resulting in high impact. Funding encourages established investigators to push their research forward toward childhood cancer breakthroughs and ultimately new clinical interventions.
Bio-Therapeutic Impact Award
The Bio-Therapeutic Impact Award accelerates the development of clinical trials for promising biologic approaches to treating childhood cancer. These approaches include, but are not limited to, immunotherapy, gene therapy and small molecules. The award, intended for investigators who are initiating clinical trials or undertaking the pre-clinical work necessary to move into the IND (investigational new drug) phase, totals the maximum of $1.5 million awarded over three years.
Center of Excellence Grants
The Centers of Excellence (COE) program will fund selected leading childhood cancer institutions with programs committed to developing and conducting early phase clinical trials for childhood cancer and with a pediatric oncology clinical pharmacology/developmental therapeutics program. The ultimate goal of this program is to expedite the development of novel therapeutic approaches for pediatric malignancies by establishing more robust Centers of Excellence in pediatric cancer drug development and through training the next generation of leaders in preclinical and clinical drug development. COE grants are $350,000 per year, renewable annually for up to 5 years. Fifty percent of the funds must be used to enhance the Center’s clinical trial infrastructure. The remaining fifty percent must be used to support the training of physician scholars in drug development. An invitation to apply will be contingent upon receipt and review of a nomination form.
Please note that the Centers of Excellence Grant is not offered every year. Please view our Grants Calendar for upcoming grant opportunities.
Crazy 8 Initiative
The Crazy 8 Initiative Award will fund research into innovative and rigorous approaches that directly address the most intractable issues in pediatric cancer research today. This award is designed to coalesce cross-disciplinary cores of scientists working collaboratively in order to accelerate the pace of discovering new cures. The budget for this award is between $1-5 million USD over four years.
These grants are designed to support the research of investigators who have a specific focus on the epidemiology of childhood cancer, early detection of childhood cancer, or the prevention of childhood cancer. Awards are $100,000 per year for two years.
These grants are designed to provide critical and significant seed funding for experienced investigators with a novel and promising approach to finding causes and cures for childhood cancers. A Letter of Intent is required. The Innovation Award amount totals $250,000 over two years. The Award may not be renewed, however, no cost extensions are allowable.
Familial RUNX1 Research Grants
The grant funds research in strategies leading to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with FPD/AML. The Grant is up to $250,000 over two years. A Letter of Intent must be submitted for competitive review. This grant is not currently being offered.
New in 2019, RUNX1 grants are being offered via an Early Career Research grant.
Phase I/II Infrastructure Grants
Doctors have identified a critical lack of funding for support personnel who speed up the process of enrolling children with cancer in clinical trials. With grants from Alex's Lemonade Stand Foundation, hospitals across the country have created new positions, specifically focused on filling this critical need, bringing the latest treatments to more children.
Please note that the Phase I/II Infrastructure grant is not offered every year. Please view our Grants Calendar for upcoming grant opportunities.
This award is designed to move hypothesis-driven research toward the clinic. A successful application will identify an unmet clinical need relevant to the care of patients with pediatric cancer and describe how the work performed will allow for the translation of hypothesis-driven research to the clinic, keeping broader clinical testing and implementation in view. A maximum of $250,000 in total costs will be awarded over two years.
Single-cell Pediatric Cancer Atlas Grant
ALSF seeks to build a Pediatric Cancer Atlas as an open resource for discovery with an initial goal of producing data that can be harmonized. ALSF seeks researchers to create datasets that profile pediatric cancers at a single-cell resolution level. Single-cell profiling can provide insights into the heterogeneity of cells in a tumor and the surrounding tumor microenvironment, as well as variability in the states of cancer cells, all of which can influence the cancer’s response to treatments. The budget for this award is $200,000 USD over one year.
As of 2015 these grants are no longer offered.
As of 2015 these grants are no longer offered.